Download PDF – AVEO Pipeline to Include Global Rights to Three Clinical-Stage and One Commercial-Stage Assets, Including Ficlatuzumab and AV-380 – BOSTON–(BUSINESS WIRE)–Mar. 15, 2021– AVEO Oncology (Nasdaq: AVEO) today announced that it will regain its rights to AV-203 outside of North America, its clinical-stage potent humanized IgG1 monoclonal antibody that targets ErbB3 (also known as HER3), following
Category: Press Release
AVEO Oncology Announces Collaboration with Bristol Myers Squibb to Evaluate FOTIVDA® (tivozanib) in Combination with OPDIVO® (nivolumab) in Pivotal Phase 3 TiNivo-2 Trial in IO Relapsed Renal Cell Carcinoma
Download PDF BOSTON–(BUSINESS WIRE)–Mar. 12, 2021– AVEO Oncology (Nasdaq: AVEO) today announced that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate FOTIVDA® (tivozanib) in combination with OPDIVO® (nivolumab), Bristol Myers Squibb’s anti-PD-1 therapy, in the pivotal Phase 3 TiNivo-2 trial in patients with advanced relapsed or refractory renal cell carcinoma
AVEO Oncology Announces Drawdown of $20 Million Tranche Under Hercules Debt Facility
Download PDF BOSTON–(BUSINESS WIRE)–Mar. 11, 2021– AVEO Oncology (Nasdaq: AVEO) today announced that it has completed a drawdown of $20 million under its previously announced $45 million loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC, “Hercules”) and its affiliates. This second tranche was made available in connection with the recent U.S. Food and Drug Administration (FDA) approval of FOTIVDA® (tivozanib). “With the additional $20 million now
AVEO Oncology Announces U.S. FDA Approval of FOTIVDA® (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma
Download PDF – FOTIVDA is the First Therapy Approved for Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma Following Two or More Prior Systemic Therapies – – AVEO Plans to Make FOTIVDA Available to Patients in the U.S. by March 31, 2021 – – Company to Host Conference Call and Webcast today, March 10, 2021, at 6:00 PM ET – BOSTON–(BUSINESS
AVEO Announces Appointment of Mike Ferraresso to Chief Commercial Officer
Download PDF BOSTON–(BUSINESS WIRE)–Mar. 10, 2021– AVEO Oncology (Nasdaq:AVEO) today announced the appointment of Mike Ferraresso to chief commercial officer. Mr. Ferraresso will be responsible for managing AVEO’s commercial strategy and operations, including the commercialization of FOTIVDA® (tivozanib). FOTIVDA is AVEO’s differentiated oral, once-daily, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) approved in the U.S. for the treatment of adult patients
AVEO Oncology to Present at the H.C. Wainwright Global Life Sciences Conference
Download PDF BOSTON–(BUSINESS WIRE)–Mar. 2, 2021– AVEO Oncology (Nasdaq: AVEO) todayannounced that Michael Bailey, president and chief executive officer of AVEO, will present at the H.C. Wainwright Global Life Sciences Conference, being held virtually on March 9-10, 2021. A replay of the pre-recorded presentation can be accessed on Tuesday, March 9, 2021 in the investors section of the Company’s website at www.aveooncology.com. A
AVEO Oncology Announces Participation at the 2021 SVB Leerink Global Healthcare Conference
Download PDF BOSTON–(BUSINESS WIRE)–Feb. 18, 2021– AVEO Oncology (Nasdaq: AVEO) todayannounced that Michael Bailey, president and chief executive officer of AVEO, will participate in a fireside chat at the 2021 SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 3:00 p.m. Eastern Time. A live webcast of the fireside chat can be accessed by visiting the investors section of the Company’s
AVEO Oncology Announces Presentation of Key Subgroup and Quality of Life Analyses from the Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma
Download PDF – Data Presented at the ASCO 2021 GU Cancers Symposium – –Sequencing Data Support Tivozanib is a Differentiated Selective VEGF TKI; Q-TWiST Quality of Life Measure Shows Significant Improvement for Tivozanib over Sorafenib – BOSTON, Mass.–(BUSINESS WIRE)–Feb. 11, 2021– AVEO Oncology (Nasdaq: AVEO) today announced the presentation of two analyses of the Company’s pivotal TIVO-3
AVEO Oncology Announces Commitment for an Incremental $10 Million Loan in Addition to Current Tranched, $35 Million Debt Facility with Hercules Capital
Download PDF – $20M Tranche Available on Approval of Tivozanib – BOSTON–(BUSINESS WIRE)–Jan. 20, 2021– AVEO Oncology (Nasdaq: AVEO) today announced that it has received a commitment letter for an incremental $10 million loan from Hercules Capital, Inc. (NYSE: HTGC, “Hercules”) and its affiliates, to be added to the current tranched, $35 million debt facility secured with Hercules in August 2020 through an amendment to the amended
AVEO Oncology Announces Results from Phase 1b Portion of DEDUCTIVE Study of Tivozanib (FOTIVDA®) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma
Download PDF – Data Presented at the 2021 ASCO GI Cancers Symposium – BOSTON–(BUSINESS WIRE)–Jan. 15, 2021– AVEO Oncology (Nasdaq: AVEO) today announced the presentation of results from the Phase 1b portion of the Phase 1b/2 DEDUCTIVE clinical trial of tivozanib (FOTIVDA®), AVEO’s vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) drug candidate, in combination